Hospital groups to appeal dismissal of 340B lawsuit

The American Hospital Association (AHA), America’s Essential Hospitals, the Association of American Medical Colleges (AAMC) and three health systems will appeal the dismissal of its lawsuit seeking to block $1.6 billion in cuts to Medicare payments made through the 340B drug discount program.

The suit had been tossed on Dec. 29, 2017, on procedural grounds, with U.S. District Court Judge Rudolph Contreras saying the plaintiffs had to wait until the reductions went into effect. That happened Jan. 1, and the groups noted in their reactions to the dismissal Contreras didn’t address the merits of their case.

“The court’s decision, while not ruling on the merits, still permits CMS to make drastic cuts to safety net hospitals that participate in the 340B program, which allows teaching hospitals to strengthen care for low-income, rural, and other underserved patients. As a result, institutions will have greater difficulty maintaining critical services that vulnerable patients often cannot access elsewhere,” said Darrell G. Kirch, MD, president and CEO of the AAMC.

Also involved in the suit are Brewer, Maine-based Eastern Maine Healthcare Systems, Detroit-based Henry Ford Health System and Henderson, North Carolina-based Park Ridge Health.

The change made by CMS would lower the reimbursement rate under 340B from the average sales price (ASP) plus 6 percent to ASP minus 22 percent. In all, $1.6 billion would be cut, though for most hospitals their total Medicare Part B revenue would be reduced by less than 5 percent.

Pharmaceutical companies have supported the cuts, saying 340B has been used by hospitals to pad profits, not help low-income patients as originally intended. In comments to Kaiser Health News, Stephen Ubl, president of the drug industry lobby Pharmaceutical Research and Manufacturers of America (PhRMA) argued the program “needs fundamental reform.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.